Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Moleculin Biotech ( (MBRX) ) just unveiled an update.
On January 20, 2026, Moleculin Biotech, Inc. used a new corporate presentation, made available on its website, as part of its investor communications, while clarifying in a regulatory filing that the materials were being furnished rather than filed under U.S. securities laws, limiting their formal incorporation into future securities filings.
The most recent analyst rating on (MBRX) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue losses, ongoing cash burn, and prior negative equity) and bearish technicals (below key moving averages with negative MACD). Positive corporate developments (clinical progress and regained Nasdaq compliance) provide some offset, while valuation is limited by ongoing losses and no dividend.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a biopharmaceutical company focused on developing drug candidates, with its activities and investor communications typically aimed at the oncology and broader life sciences markets.
Average Trading Volume: 322,148
Technical Sentiment Signal: Sell
Current Market Cap: $12.81M
Learn more about MBRX stock on TipRanks’ Stock Analysis page.